Furthermore a Phase 2a research for BNC210 in human patients suffering stress and anxiety is prepared with the trial expected to commence during Q1, 2015 in the united kingdom. These trials mark essential steps in the advancement of BNC210 and can placement it for partnering possibilities. We're wanting to make contact with the clinic with BNC210 and unlock the potential of the compound, stated Dr Deborah Rathjen, Bionomics' Managing and CEO Director. We anticipate this to become a pivotal yr in its advancement and given the info so far are confident it’ll be another Bionomics medication candidate which will attract the curiosity of big pharma businesses. Data out of this trial is normally anticipated in Q3, 2015.As a result of this determination, reported product sales for the years finished December 31, 2010 and 2009 have already been reduced by $5.9 million and $7.5 million, respectively and product sales in the fourth quarter of 2010 and 2009 have been decreased by $1.3 million and $1.6 million, respectively. The influence from these discontinued product lines on the Company’s current and previously reported net gain in all periods is separately reported as ‘Loss from discontinued functions, net of taxes’ in its Consolidated Statements of Procedures. Net assets of $3.1 million identifiable with these discontinued product lines is reported in the Company’s December 31, 2010 Consolidated Balance Sheet as ‘Assets held for sale.’ REVENUE Total revenue from continuing operations for the fourth quarter of 2010 was $92.6 million, compared to $90.9 million for the fourth quarter of 2009.